Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
RecruitingOBSERVATIONAL
Enrollment
800
Participants
Timeline
Start Date
February 5, 2025
Primary Completion Date
February 5, 2026
Study Completion Date
February 5, 2026
Conditions
Dysbiosis
Trial Locations (1)
67091
RECRUITING
Service de Pneumologie - CHU de Strasbourg - France, Strasbourg
All Listed Sponsors
lead
University Hospital, Strasbourg, France
OTHER
NCT07191171 - Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter